These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 37595663)

  • 1. Intranasal inoculation of female BALB/c mice with replication-deficient human adenovirus type 5 expressing SARS-CoV-2 nucleocapsid protein aggravates lung pathology upon re-encountering the antigen.
    Cao J; Gu H; Zhang X; Yun H; Li J; Si CY; Zhang J; Wang H
    Virus Res; 2023 Oct; 335():199201. PubMed ID: 37595663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice.
    He J; Huang JR; Zhang YL; Zhang J
    J Med Virol; 2021 Apr; 93(4):1923-1925. PubMed ID: 33386773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK
    Antiviral Res; 2023 Aug; 216():105656. PubMed ID: 37327877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.
    Castro JT; Azevedo P; Fumagalli MJ; Hojo-Souza NS; Salazar N; Almeida GG; Oliveira LI; Faustino L; Antonelli LR; Marçal TG; Augusto M; Valiate B; Fiorini A; Rattis B; Ramos SG; Piccin M; Nonato OC; Benevides L; Magalhães R; Cassaro B; Burle G; Doro D; Kalil J; Durigon E; Salazar A; Caballero O; Santiago H; Machado A; Silva JS; da Fonseca F; Fernandes AP; Teixeira SR; Gazzinelli RT
    Nat Commun; 2022 Aug; 13(1):4831. PubMed ID: 35977933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong SARS-CoV-2 N-Specific CD8
    Ferrantelli F; Chiozzini C; Manfredi F; Leone P; Spada M; Di Virgilio A; Giovannelli A; Sanchez M; Cara A; Michelini Z; Federico M
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
    Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
    Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
    Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
    Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
    J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization.
    Shi SQ; Peng JP; Li YC; Qin C; Liang GD; Xu L; Yang Y; Wang JL; Sun QH
    Mol Immunol; 2006 Apr; 43(11):1791-8. PubMed ID: 16423399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection.
    Wang S; Xu L; Mu T; Qin M; Zhao P; Xie L; Du L; Wu Y; Legrand N; Mouchain K; Fichet G; Liu Y; Yin W; Zhao J; Ji M; Gong B; Klein M; Wu K
    Front Cell Infect Microbiol; 2022; 12():979641. PubMed ID: 36405962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.
    Feng L; Wang Q; Shan C; Yang C; Feng Y; Wu J; Liu X; Zhou Y; Jiang R; Hu P; Liu X; Zhang F; Li P; Niu X; Liu Y; Zheng X; Luo J; Sun J; Gu Y; Liu B; Xu Y; Li C; Pan W; Zhao J; Ke C; Chen X; Xu T; Zhong N; Guan S; Yuan Z; Chen L
    Nat Commun; 2020 Aug; 11(1):4207. PubMed ID: 32826924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.